Table 2.
Correlation among fibroblast growth factor receptor 1 amplification, MYC expression and clinicopathological features1
| Variables |
FGFR1, n (%) |
MYC, n (%) |
||||
| No amplification | Amplification | P value | No expression | Expression | P value | |
| Age (yr) | ||||||
| ≤ 60 | 30/44 (68.2) | 14/44 (31.8) | 0.058 | 18/46 (39.1) | 28/46 (60.9) | 0.862 |
| > 60 | 106/129 (82.2) | 23/129 (17.8) | 56/134 (41.8) | 78/134 (58.2) | ||
| Smoking | ||||||
| No | 21/28 (75) | 7/28 (25) | 0.619 | 12/28 (42.9) | 6/28 (57.1) | 0.836 |
| Yes | 115/145 (79.3) | 30/145 (20.7) | 61/151 (40.4) | 90/151 (59.6) | ||
| Histological grade | ||||||
| WD | 29/34 (85.3) | 5/34 (14.7) | 0.350 | 17/35 (48.6) | 18/35 (51.4) | 0.267 |
| MD | 90/117 (76.9) | 27/117 (23.1) | 43/119 (36.1) | 76/119 (63.9) | ||
| PD | 11/16 (68.8) | 5/16 (31.2) | 10/18 (55.6) | 8/18 (44.4) | ||
| Others | 6/6 (100) | 0/6 (0) | 4/8 (50) | 4/8 (50) | ||
| Localization | ||||||
| Upper | 6/7 (85.7) | 1/7 (14.3) | 0.981 | 4/7 (57.1) | 3/7 (42.9) | 0.688 |
| Middle | 34/42 (81) | 8/42 (19) | 20/44 (45.5) | 24/44 (54.5) | ||
| Lower | 86/111 (77.5) | 25/111 (22.5) | 45/116 (38.8) | 71/116 (61.2) | ||
| EGJ | 8/10 (80) | 2/10 (20) | 4/10 (40) | 6/10 (60) | ||
| T | ||||||
| 1 | 66/80 (82.5) | 14/80 (17.5) | 0.602 | 22/81 (27.2) | 59/81 (72.8) | < 0.001 |
| 2 | 12/16 (75) | 4/16 (25) | 6/17 (35.3) | 11/17 (64.7) | ||
| 3 | 55/73 (75.3) | 18/73 (24.7) | 43/78 (55.1) | 35/78 (44.9) | ||
| 4 | 3/4 (75) | 1/4 (25) | 3/4 (75) | 1/4 (24) | ||
| N | ||||||
| 0 | 73/90 (81.1) | 17/90 (18.9) | 0.460 | 30/92 (32.6) | 62/92 (67.4) | 0.023 |
| 1-3 | 63/83 (75.9) | 20/83 (24.1) | 44/88 (50) | 44/88 (50) | ||
| Stage | ||||||
| I | 51/62 (82.3) | 11/62 (17.7) | 0.694 | 18/63 (28.6) | 45/64 (71.4) | < 0.001 |
| II | 40/52 (76.9) | 12/52 (23.1) | 17/53 (32.1) | 36/53 (67.9) | ||
| III | 45/59 (76.3) | 14/59 (23.7) | 39/64 (60.9) | 25/64 (39.1) | ||
1
Differences in the proportions of fibroblast growth factor receptor 1 (FGFR1) amplification and MYC expression according to the clinicopathological variables were compared using Fisher’s exact test. WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated; EGJ: Esophagogastric junction.